earnings
confidence high
sentiment neutral
materiality 0.70
Glaukos Q2 net sales $72.7M, down 7% YoY; raises FY2022 guidance to $275-280M
GLAUKOS Corp
2022-Q2 EPS reported
-$0.85
revenue$140,366,000
- Net sales of $72.7M in Q2 2022, down 7% YoY; glaucoma $56.1M, corneal health $16.6M.
- GAAP net loss of $45.5M ($0.96 EPS) vs loss of $17.5M ($0.38) in Q2 2021; includes $10M IPR&D charge for iVeena licensing.
- Non-GAAP net loss of $39.1M ($0.83) vs $10.1M ($0.22) in prior year.
- Raised 2022 net sales guidance to $275-280M from prior $270-275M.
- Ended Q2 with ~$400M cash and short-term investments.